Chronic Myeloid Leukemia (CML)NCT07740603
Study of CD38 and CD56 in Chronic Myeloid Leukemia
An observational study of Chronic Myeloid Leukemia (CML), run by Sohag University.
Trial summary
Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow. The aim of the study is to study expression of CD38 and CD56 in patients with Chronic myeloid leukemia. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Chronic Myeloid Leukemia (CML)
- What is being tested?
- cd 38 and cd 56
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2026to 1 Jul 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: patients in sohag city
Who may be able to join
- patients with chronic myeloid leukemia
Who cannot join
- other hematological diseases
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Aberrant Expression of CD56 on CD38 Positive Neutrophils as a Novel Diagnostic Tool in Chronic Myeloid Leukemia
Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow.
The aim of the study is to study expression of CD38 and CD56 in patients with Chronic myeloid leukemia.
- Conditions
- Chronic Myeloid Leukemia (CML)
- Being tested
- cd 38 and cd 56
- Medical subject headings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cd 38 and cd 56Diagnostic test
prescence of high percentage of cd38 and cd 56
| Study group | Role | What they receive |
|---|---|---|
| chronic myeloid leukemia group | Not described Receives: Diagnostic Test: cd 38 and cd 56 | |
| healthy group | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
an increased change in cd 38 and cd 56 in chronic leukemic patients
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2026
- Study start1 Sep 2026 (estimated)
- Primary completion1 Jun 2027 (estimated)
- Study completion1 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Myeloid Leukemia (CML)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mennatallah Mostafa Zaki, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07740603
- Sponsor's protocol ID
- Soh-Med-26-6-9MS
- Status last verified
- Aug 2026
- First submitted
- 25 Jul 2026
- Last updated
- 5 Aug 2026
- Results posted
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Aberrant Expression of CD56 on CD38 Positive Neutrophils as a Novel Diagnostic Tool in Chronic Myeloid Leukemia
- ClinicalTrials.gov ID
- NCT07740603
- Acronym / sponsor ID
- Soh-Med-26-6-9MS
- Conditions
- Chronic Myeloid Leukemia (CML)
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 1 Jun 2027 (estimated)
- Study completion
- 1 Jul 2027 (estimated)
- First posted
- 31 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow.
The aim of the study is to study expression of CD38 and CD56 in patients with Chronic myeloid leukemia.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| chronic myeloid leukemia group | – | Diagnostic Test: cd 38 and cd 56 |
| healthy group | – | – |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- patients in sohag city
Key inclusion criteria (1 listed)
- patients with chronic myeloid leukemia
Key exclusion criteria (1 listed)
- other hematological diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cd 38 and cd 56prescence of high percentage of cd38 and cd 56 | Diagnostic test | chronic myeloid leukemia group |
Primary outcome
an increased change in cd 38 and cd 56 in chronic leukemic patients
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Chronic Myeloid Leukemia (CML)
RecruitingPhase 1
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Malignancy, Hematologic, Neoplasms, Hematologic
RecruitingPhase 2
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
Active, not recruitingPhase 2
Cord Blood Transplant in Adults With Blood Cancers
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
RecruitingPhase 1
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
RecruitingPhase 2
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Myeloid Leukemia (CML), run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Menna Mostafa Zaki (01152386116, mennazaki133@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
an increased change in cd 38 and cd 56 in chronic leukemic patients (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2026.